eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Carboplatin and paclitaxel with or without bevacizumab in treating patients with stage III or stage IV ovarian epithelial, primary peritoneal cancer, or fallopian tube cancer

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Resource Description
    Most women with ovarian cancer are not diagnosed until the cancer has spread to the peritoneum (the lining of the abdominal cavity) or beyond. The standard treatment for advanced ovarian cancer is surgery, both to establish the stage and type of cancer and to remove as much cancerous tissue as possible, followed by chemotherapy with drugs such as carboplatin and paclitaxel. Despite aggressive treatment, however, the survival rate for advanced ovarian cancer remains low. In this trial, women who have undergone initial surgery for ovarian cancer or primary peritoneal cancer (which is biologically similar to ovarian cancer) will receive standard intravenous chemotherapy. Some women will also receive concurrent treatment with a biologic agent called bevacizumab. Bevacizumab blocks the activity of a protein called vascular endothelial growth factor, which helps tumors form new blood vessels needed for continued growth and spread. Following chemotherapy, some of the bevacizumab-treated women will receive additional courses of bevacizumab.
  4. Additional Name
    Phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women with newly diagnosed, previously untreated, suboptimal advanced stage epithelial ovarian, primary peritoneal cancer, or fallopian tube cancer
  5. Contact
    Berenberg, Jeffrey
  6. PI
    Berenberg, Jeffrey
  7. Topic
    peritoneal carcinoma
  8. Topic
    fallopian tube cancer
  9. Topic
    ovarian cancer
  10. Study Population
    Females aged 18 and older with histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer.
  11. Website(s)
  12. Website(s)
  13. Funded by
    Gynecologic Oncology Group
  14. Phase
    Phase 3 clinical trial
  15. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016